Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab — Mara Persano (2024) | RDL Network
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
Article 2024 en
Authors
MP
Mara Persano
MR
Margherita Rimini
TT
Toshifumi Tada
Abstract
1 min read
As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.
Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Hye Yeon Lim, José Presa, Gianluca Masi, Francesca Bergamo, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, F. Piscaglia, Stefano Cascinu, M. Scartozzi
Parissa Tabrizian, Rebecca Marino, Sherrie Bhoori, Marcus Zeitlhoefler, Neil Mehta, Vanessa Banz, Salvatore Gruttadauria, Massimo Iavarone, Chiara Mazzarelli, Nicolò Simonotti, Francis Y. Yao, Vincenzo Mazzaferro, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.